Published Papers & Misc - Yokota Takanori

Division display  181 - 200 of about 215 ／  All the affair displays >>

  1. Yutaro Asami, Kotaro Yoshioka, Kazutaka Nishina, Tetsuya Nagata, Takanori Yokota. Drug delivery system of therapeutic oligonucleotides. Drug Discov Ther. 2016; 10 (5): 256-262. ( PubMed, DOI )

  2. M Ichijo, E Iwasawa, Y Numasawa, K Miki, S Ishibashi, M Tomita, H Tomimitsu, T Kamata, H Fujigasaki, S Shintani, H Mizusawa. Significance of Development and Reversion of Collaterals on MRI in Early Neurologic Improvement and Long-Term Functional Outcome after Intravenous Thrombolysis for Ischemic Stroke. AJNR Am J Neuroradiol. 2015.10; 36 (10): 1839-1845. ( PubMed, DOI )

  3. Yoneyama M, Mitoma H, Higuma M, Sanjo N, Yokota T, Terashi H. Ambulatory Gait Behavior in Patients with Dementia: A Comparison with Parkinson's Disease. IEEE Trans Neural Syst Rehabil Eng. 2015.09;

  4. Nakamaura Y, Ae R, Takumi I, Sanjo N, Kitamoto T, Yamada M, Mizusawa H. Descriptive epidemiology of prion disease in Japan: 1999-2012. J Epidemiol. 2015; 25 (1): 8-14.

  5. Pedroso JL, Abrahao A, Ishikawa K, Raskin S, de Souza PV, de Rezende Pinto WB, Braga-Neto P, de Albuquerque MV, Mizusawa H, Barsottini OG. When should we test patients with familial ataxias for SCA31? A misdiagnosed condition outside Japan? J Neurol Sci. 2015; 355 (1-2): 206-208.

  6. Ohmori H, Hara A, Ishikawa K, Mizusawa H, Ando Y. Clinical characteristics of combined cases of spinocerebellar ataxia types 6 and 31. J Neurogenet. 2015; 29 (2-3): 80-4.

  7. Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, Dürr A, Brice A, Takashima H, Kikuchi A, Aoki M, Ishiura H, Yasuda T, Date H, Ahsan B, Iwata A, Goto J, Ichikawa Y, Nakahara Y, Momose Y, Takahashi Y, Hara K, Kakita A, Yamada M, Takahashi H, Onodera O, Nishizawa M, Watanabe H, Ito M, Sobue G, Ishikawa K, Mizusawa H, Kanai K, Hattori T, Kuwabara S, Arai K, Koyano S, Kuroiwa Y, Hasegawa K, Yuasa T, Yasui K, Nakashima K, Ito H, Izumi Y, Kaji R, Kato T, Kusunoki S, Osaki Y, Horiuchi M, Kondo T, Murayama S, Hattori N, Yamamoto M, Murata M, Satake W, Toda T, Filla A, Klockgether T, Wüllner U, Nicholson G, Gilman S, Tanner CM, Kukull WA, Stern MB, Lee VM, Trojanowski JQ, Masliah E, Low PA, Sandroni P, Ozelius LJ, Foroud T, Tsuji S. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol. 2015; 2 (4): 417-426.

  8. Ozaki K, Irioka T, Ishikawa K, Mizusawa H. CADASIL with a novel NOTCH3 mutation (Cys478Tyr). J Stroke Cerebrovasc Dis. 2015; 24 (3): e61-62.

  9. Nishida Y, Ueda A, Ando Y, Ichikawa T. Skin biopsy-based diagnosis of CADASIL with atypical MRI findings. Intern Med. 2015; 54 (5): 537-538.

  10. Takenouchi T, Ohyagi M, Torii C, Kosaki R, Takahashi T, Kosaki K. Porencephaly in a fetus and HANAC in her father: variable expression of COL4A1 mutation. Am J Med Genet A. 2015; 167A (1): 156-158.

  11. Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, Tanihata J, Nakamura A, Nagaraju K, Yokota T. Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids. 2015; 4 e225.

  12. Kimura K, Morita H, Daimon M, Kawata T, Nakao T, Lee SL, Hirokawa M, Ebihara A, Nakajima T, Ozawa T, Yonemochi Y, Aida I, Motoyoshi Y, Mikata T, Uchida I, Komori T, Kitao R, Nagata T, Takeda S, Komaki H, Segawa K, Takenaka K, Komuro I . Prognostic impact of venous thromboembolism in patients with Duchenne muscular dystrophy: Prospective multicenter 5-year cohort study. Int J Cardiol. 2015; 191 178-180.

  13. Masaki Y, Inde T, Nagata T, Tanihata J, Kanamori T, Seio K, Takeda S, Sekine M. Enhancement of exon skipping in mdx52 mice by 2’-O-methyl-2-thioribothymidine incorporation into phosphorothioate oligonucleotides. Med Chem Commun. 2015; 6 630-633.

  14. Colangelo CM, Ivosev G, Chung L, Abbott T, Shifman M, Sakaue F, Cox D, Kitchen RR, Burton L, Tate SA, Gulcicek E, Bonner R, Rinehart J, Nairn AC, Williams KR. Development of a highly automated and multiplexed targeted proteome pipeline and assay for 112 rat brain synaptic proteins. Proteomics. 2015; 15 (7): 1202-1214.

  15. Yagi Y, Yokote H, Watanabe Y, Amino T, Kamata T, Kusunoki S. Taste impairment in Miller Fisher syndrome. Neurol Sci. 2015; 36 (5): 809-810.

  16. Ozaki K, Sanjo N, Ishikawa K, Higashi M, Hattori T, Tanuma N, Miyata R, Hayashi M, Yokota T, Okawa A, Mizusawa H. Elevation of 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of three patients with superficial siderosis. Neurol Clin Neurosci. 2015; 3 (3): 108-110.

  17. Ohyagi M, Nakamura K, Watanabe M, Fujigasaki H. Embolic stroke during apixaban therapy for left atrial appendage thrombus. J Stroke Cerebrovasc Dis. 2015; 24 (4): e101-102.

  18. Ishibashi K, Miura Y, Ishikawa K, Ishii K, Ishiwata K. Decreased metabotropic glutamate receptor type 1 availability in a patient with spinocerebellar ataxia type 6: A (11)C-ITMM PET study. J Neurol Sci. 2015; 355 (1-2): 202-205.

  19. Yabe I, Matsushima M, Yoshida K, Ishikawa K, Shirai S, Takahashi I, Sasaki H. Rare frequency of downbeat positioning nystagmus in spinocerebellar ataxia type 31. J Neurol Sci. 2015; 350 (1-2): 90-92.

  20. Obayashi M, Stevanin G, Synofzik M, Monin ML, Duyckaerts C, Sato N, Streichenberger N, Vighetto A, Desestret V, Tesson C, Wichmann HE, Illig T, Huttenlocher J, Kita Y, Izumi Y, Mizusawa H, Schöls L, Klopstock T, Brice A, Ishikawa K, Dürr A. Spinocerebellar ataxia type 36 exists in diverse populations and can be caused by a short hexanucleotide GGCCTG repeat expansion. J Neurol Neurosurg Psychiatry. 2015; 86 (9): 986-995.

< PREV - NEXT >

To the head of this page.▲